91904-36-8

Basic information

• Product Name: [2-[(4-METHYLPIPERAZIN-1-YL)METHYL]PHENYL]METHANOL
• Synonyms: [2-[(4-METHYLPIPERAZIN-1-YL)METHYL]PHENYL]METHANOL;{2-[(4-Methylpiperazin-1-yl)methyl]phenyl}methanol 97%
• CAS NO: 91904-36-8
• Molecular Formula: C₁₃H₂₀N₂O
• Molecular Weight: 220.31
• Mol File: 91904-36-8.mol
• Article Data: 1

Chemical Properties

• Melting Point: 62 °C
• Boiling Point: 341.5°Cat760mmHg
• Flash Point: 160°C
• Appearance: /
• Density: 1.097g/cm³
• Vapor Pressure: 3.08E-05mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: [2-[(4-METHYLPIPERAZIN-1-YL)METHYL]PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [2-[(4-METHYLPIPERAZIN-1-YL)METHYL]PHENYL]METHANOL(91904-36-8)
• EPA Substance Registry System: [2-[(4-METHYLPIPERAZIN-1-YL)METHYL]PHENYL]METHANOL(91904-36-8)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 91904-36-8(Hazardous Substances Data)

Usage

General Description

[2-[(4-Methylpiperazin-1-yl)methyl]phenyl]methanol is a chemical compound with a molecular formula of C14H20N2O. It is a derivative of piperazine and is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds. The presence of a piperazine group in the molecule makes it a potential candidate for drug design and development. It is also known to exhibit some pharmacological properties, making it an important target for medicinal chemistry research. Additionally, the compound's structural features make it suitable for modification and optimization for specific biological activities. Overall, [2-[(4-Methylpiperazin-1-yl)methyl]phenyl]methanol plays a significant role in drug discovery and development due to its versatile chemical nature.

InChI:InChI=1/C13H20N2O/c1-14-6-8-15(9-7-14)10-12-4-2-3-5-13(12)11-16/h2-5,16H,6-11H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 4122-56-9 methyl o-formylbenzoate 

Downstream Products

• 628311-19-3 2-[(4-methylpiperazin-1-yl)methyl]benzaldehyde 

Relevant articles and documents

Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBβ and Autophagy

Autophagy inhibition is emerging as a promising anticancer strategy. We recently reported that the circadian nuclear receptor REV-ERBβ plays an unexpected role in sustaining cancer cell survival when the autophagy flux is compromised. We also identified 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol, 1 (ARN5187), as a novel dual inhibitor of REV-ERBβ and autophagy. 1 had improved cytotoxicity against BT-474 breast cancer cells compared to chloroquine, a clinically relevant autophagy inhibitor. Here, we present the results of structure-activity studies, based around 1, that disclose the first class of dual inhibitors of REV-ERBβ and autophagy. This study led to identification of 18 and 28, which were more effective REV-ERBβ antagonists than 1 and were more cytotoxic to BT-474. The combination of optimal chemical and structural moieties of these analogs generated 30, which elicited 15-fold greater REV-ERBβ inhibitory and cytotoxic activities compared to 1. Furthermore, 30 induced death in a panel of tumor cell lines at doses 5-50 times lower than an equitoxic amount of chloroquine but did not affect the viability of normal mammary epithelial cells.